0001209191-21-029042.txt : 20210429
0001209191-21-029042.hdr.sgml : 20210429
20210429173104
ACCESSION NUMBER: 0001209191-21-029042
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210429
FILED AS OF DATE: 20210429
DATE AS OF CHANGE: 20210429
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GADICKE ANSBERT
CENTRAL INDEX KEY: 0001134655
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21872340
MAIL ADDRESS:
STREET 1: THE JOHN HANCOCK TOWER
STREET 2: 200 CLARENDON STREET, 54TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management LP
CENTRAL INDEX KEY: 0001687078
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21872336
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P.
CENTRAL INDEX KEY: 0001691428
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21872338
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Innovations Fund GP LLC
CENTRAL INDEX KEY: 0001857903
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21872335
BUSINESS ADDRESS:
STREET 1: C/O MPM CAPITAL
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: C/O MPM CAPITAL
STREET 2: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM Oncology Impact Management GP LLC
CENTRAL INDEX KEY: 0001721035
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21872334
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oncology Impact Fund (Cayman) Management L.P.
CENTRAL INDEX KEY: 0001721036
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21872337
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6174259200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MPM ONCOLOGY INNOVATIONS FUND LP
CENTRAL INDEX KEY: 0001719960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40366
FILM NUMBER: 21872339
BUSINESS ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-425-9200
MAIL ADDRESS:
STREET 1: 450 KENDALL STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER NAME:
FORMER CONFORMED NAME: MPM ONCOLOGY INNOVATIONS FUND L.P.
DATE OF NAME CHANGE: 20171017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Werewolf Therapeutics, Inc.
CENTRAL INDEX KEY: 0001785530
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 823523180
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVENUE
STREET 2: SUITE 210
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
BUSINESS PHONE: 617-952-0555
MAIL ADDRESS:
STREET 1: 1030 MASSACHUSETTS AVENUE
STREET 2: SUITE 210
CITY: CAMBRIDGE
STATE: MA
ZIP: 02138
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2021-04-29
0
0001785530
Werewolf Therapeutics, Inc.
HOWL
0001134655
GADICKE ANSBERT
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001719960
MPM ONCOLOGY INNOVATIONS FUND LP
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001691428
UBS Oncology Impact Fund L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001721036
Oncology Impact Fund (Cayman) Management L.P.
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001687078
MPM Oncology Impact Management LP
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001857903
MPM Oncology Innovations Fund GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
0001721035
MPM Oncology Impact Management GP LLC
C/O MPM CAPITAL
450 KENDALL STREET
CAMBRIDGE
MA
02142
0
0
1
0
Common Stock
461408
I
See Footnote
Series A Preferred Stock
Common Stock
4477742
I
See Footnote
Series B Preferred Stock
Common Stock
1488033
I
See Footnote
Warrant (Right to Buy)
0.09
2024-12-05
Common Stock
8031
I
See Footnote
Warrant (Right to Buy)
0.09
2025-04-09
Common Stock
8031
I
See Footnote
Warrant (Right to Buy)
0.09
2025-08-13
Common Stock
42842
I
See Footnote
The shares are held by MPM Asset Management LLC ("AM LLC"). Ansbert Gadicke is a member of AM LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Each share of Series A Preferred Stock and Series B Preferred Stock is convertible into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
The shares are held as follows: 2,087,358 by MPM BioVentures 2014, L.P. ("BV 2014"), 139,224 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 71,848 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 457,643 by MPM Oncology Innovations Fund, L.P. ("MPM OIF") and 1,721,669 by UBS Oncology Impact Fund L.P. ("UBS Oncology"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of BV LLC. MPM Oncology Innovations Fund GP LLC ("MPM OIF GP") is the general partner of MPM OIF. Ansbert Gadicke is a manager of MPM OIF GP. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC.
Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The shares are held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
Immediately exercisable.
The warrants are held as follows: 3,647 by BV 2014, 243 by BV 2014(B), 125 by AM BV2014 and 4,016 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
The warrants are held as follows: 17,023 by BV 2014, 1,135 by BV 2014(B), 585 by AM BV2014, 5,355 by MPM OIF and 18,744 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.
/s/ Ansbert Gadicke
2021-04-29
/s/ Ansbert Gadicke, manager of MPM Oncology Innovations Fund GP LLC, the general partner of MPM Oncology Innovations Fund L.P.
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P., the GP of UBS Oncology Impact Fund L.P.
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP, the general partner of Oncology Impact Fund (Cayman) Management L.P.
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC, the general partner of MPM Oncology Impact Management LP
2021-04-29
/s/ Ansbert Gadicke, manager of MPM Oncology Innovations Fund GP LLC
2021-04-29
/s/ Ansbert Gadicke, managing member of MPM Oncology Impact Management GP LLC
2021-04-29